Filing Flows › Bionano Genomics (BNGO) › Q3 2025
Bionano Genomics (BNGO) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 13, 2025
Bionano Genomics (BNGO) reported revenue of $7.4M for the third quarter 2025 (Q3 2025), +21% from a year earlier and +9% from the quarter before. Operating margin was -115.9%, net loss $8.5M (115.4% of revenue).
Bionano Genomics, Q3 2025: revenue $7.4M (+21% year over year), operating margin -115.9%, net loss $8.5M, operating cash flow −$5.9M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $7.4M | +9% | +21% |
| Operating profit | −$8.5M | — | — |
| Net earnings | −$8.5M | — | — |
| Operating cash flow | −$5.9M | — | — |
What changed
Revenue was $7.4M in Q3 2025, up 21% year over year and up 9% from the previous quarter. Consumables was the largest line at 51% of revenue. Consumables added $440K year over year (up 13%), 34% of the total change.
Operating costs exceeded revenue by $8.5M, an operating margin of -115.9%. Total costs fell 68% while revenue rose 21%. The quarter ended with a net loss of $8.5M, wider than the previous quarter's $6.9M loss.
Operating cash flow was −$5.9M. Non-cash charges added back $2.4M of depreciation and amortization and $941K of share-based compensation. Working capital and other items used $733K.
Questions
What was Bionano Genomics' revenue in the third quarter 2025?
Bionano Genomics (BNGO) reported revenue of $7.4M for the third quarter 2025 (Q3 2025), +21% from a year earlier and +9% from the quarter before.
Was Bionano Genomics profitable in the third quarter 2025?
Operating loss was $8.5M (-115.9% of revenue) and net loss $8.5M.
Source: Bionano Genomics 10-Q on SEC EDGAR.